myNEO
Ottergemsesteenweg-Zuid 808 B511
9000 Gent
BE
myNEO
Foundation date
01/12/2018
Sector
#Biotechnology / R&D ServicesSubsector
- #Therapeutics - Cell therapy
- #Therapeutics - Peptides
- #R&D Services - Bioinformatics
- #R&D Services - CRO (Contract Research Organization)
- #R&D Services - Genomics
Therapeutic areas
myNEO is a distinguished Belgian biotech powerhouse dedicated to pioneering breakthrough immunotherapies tailored to target diverse tumor profiles. myNEO's discovery platform leverages immuno-genomic datasets to identify tumor alterations and unveil promising and largely untapped immunotherapeutic targets. In vivo studies underscore myNEO's prowess in identifying effective tumor targets. myNEO is now advancing development of its proprietary 'camyotopes', a class of long non-coding RNAs that shows selective translation in tumor tissue and a robust immunogenic multi-targeted response against the tumor. The lead program CAMYO-01 will validate the MOA of the camyotopes in a CRC phase I/II trial, while simultaneously expanding the development pipeline to other indications.
Upcoming events
All events-
1109 '24
The Leuven Protein Aggregation Meeting (2nd edition)
Event by: VIB -
1010 '24
-
0411 '24
BIO-Europe® 2024 - 30th Annual International Partnering Conference
Event by: EBD Group
Latest news
More news-
Antonin (Tony) de Fougerolles appointed as new Chair of etherna
Tuesday July 16th 2024
Read more
-
ONTOFORCE Achieves ISO 27001:2022 Certification: A Milestone in Information Security and Trust
Tuesday July 16th 2024
Read more
-
Ghent University spin-off Trince wins Nature Spinoff Prize
Monday July 15th 2024
Read more
Jobs
More jobsMore info?
Ellen Telleir
Communication Coordinator